A Dravet syndrome genetic test usually looks for disease-causing variants in SCN1A, the gene most often responsible for this severe developmental and epileptic encephalopathy. Testing is considered when an infant or young child has prolonged, recurrent, or unusually severe seizures—especially seizures triggered by fever, warmth, vaccination-related fever, or illness—after previously typical early development. A pathogenic SCN1A result can support early diagnosis, steer treatment away from medications that may worsen seizures, guide emergency planning, and clarify recurrence risk. It is not a stand-alone diagnosis: SCN1A variants cause a wide spectrum ranging from mild febrile seizures to Dravet syndrome, and some people with a classic Dravet presentation have no detectable SCN1A variant. The laboratory must assess small sequence changes and, when possible, deletions or duplications. Results should be interpreted with seizure onset, seizure type, development, electroencephalography, family history, and the known functional effect of the specific variant.
- Pathogenic SCN1A variants are found in most, but not all, people with clinically diagnosed Dravet syndrome.
- A positive SCN1A result does not automatically mean Dravet syndrome because the same gene is linked to milder and different epilepsy phenotypes.
- Most Dravet-associated SCN1A variants arise de novo, but parental mosaicism can create a recurrence risk even when parental blood tests are negative.
- Sodium-channel-blocking antiseizure medicines can worsen seizures in many people with SCN1A loss-of-function Dravet syndrome.
- A negative single-gene test may lead to deletion/duplication analysis, an epilepsy panel, exome sequencing, or genome sequencing.
Table of Contents
- When Dravet Syndrome and SCN1A Testing Are Suspected
- What SCN1A Does and How Variants Cause Disease
- Testing Methods and Sample Types
- Interpreting Positive, Uncertain, and Negative Results
- How Results Can Change Treatment and Safety
- Inheritance, Parental Mosaicism, and Family Risk
- Limits of Genotype Prediction
- Next Steps After Testing
When Dravet Syndrome and SCN1A Testing Are Suspected
Dravet syndrome usually begins in the first year of life in an infant whose development initially appears typical. The first recognized seizure is often prolonged and may involve one side of the body, both sides, or repeated convulsions. Fever is a common trigger, but a seizure does not have to occur during a high fever. A warm bath, hot weather, exertion, illness, vaccination-related fever, bright or patterned light, and sleep deprivation can lower the seizure threshold.
Early electroencephalograms and brain magnetic resonance imaging may be normal. That can delay recognition if clinicians expect a clear abnormality after the first event. Over time, additional seizure types may appear, including generalized tonic-clonic, hemiclonic, myoclonic, focal impaired-awareness, atypical absence, and status epilepticus. Seizures often become resistant to standard therapy.
Development may slow during the second or third year, although timing and severity vary. Language, coordination, attention, sleep, behavior, gait, and autonomic function can be affected. Developmental difficulties are not explained only by visible seizures; the underlying channel disorder, repeated prolonged seizures, interictal epileptic activity, medication effects, and other factors may all contribute.
Genetic testing should be considered early when the seizure pattern is concerning. Features that increase suspicion include:
- A prolonged convulsive seizure before 12 months, especially before 7 months.
- Recurrent prolonged seizures or status epilepticus.
- Hemiclonic seizures that alternate sides.
- Seizures triggered by fever, heat, hot water, or vaccination-related temperature rise.
- Several seizure types emerging during infancy or early childhood.
- Worsening with sodium-channel-blocking antiseizure medication.
- Initially typical development followed by slowing, ataxia, or behavioral concerns.
No single feature is required. Some children have shorter first seizures, later onset, or less obvious temperature sensitivity. Adults with longstanding drug-resistant epilepsy and developmental disability may also merit testing when childhood records are incomplete. A molecular diagnosis in adulthood can still affect medication choice, emergency planning, family counseling, and eligibility for syndrome-specific care or research.
Dravet syndrome remains a clinical diagnosis supported by genetics. A child with a convincing phenotype may be diagnosed and treated accordingly even when SCN1A testing is negative. Conversely, an SCN1A variant found after a single febrile seizure must be interpreted cautiously because many children with febrile seizures do not have Dravet syndrome.
What SCN1A Does and How Variants Cause Disease
SCN1A provides instructions for the alpha subunit of the Nav1.1 voltage-gated sodium channel. Sodium channels help nerve cells generate and transmit electrical signals. Nav1.1 is especially important in inhibitory interneurons, which restrain excessive network activity. When these cells cannot fire normally, the brain’s balance shifts toward excitation and seizures become more likely.
Most classic Dravet syndrome results from loss of function in one SCN1A copy, also called haploinsufficiency. The altered copy produces little or no functional Nav1.1 channel, leaving the person with insufficient channel activity. Loss-of-function variants include nonsense variants, frameshift variants, splice variants, whole-gene or multi-exon deletions, and some missense variants that impair channel function.
Missense variants change one amino acid in the protein. Their effects are more difficult to predict because they can reduce function, alter channel gating, or occasionally increase function. The location of the change, laboratory functional studies, previous reports, population data, inheritance, and clinical phenotype all contribute to classification.
Not every SCN1A disorder is caused by loss of function. Gain-of-function variants can produce different developmental and epileptic encephalopathies, sometimes with neonatal onset, movement abnormalities, arthrogryposis, or other features. This distinction matters because a medication that worsens loss-of-function Dravet syndrome may help selected gain-of-function disorders. Treatment should not be based on the gene name alone when the variant mechanism and phenotype point elsewhere.
SCN1A is associated with a continuum that includes genetic epilepsy with febrile seizures plus, familial hemiplegic migraine, febrile seizures, focal epilepsy, Dravet syndrome, and other developmental epileptic encephalopathies. The same broad variant category can produce different severity in different people. A report must therefore avoid statements such as “SCN1A positive equals Dravet” without clinical correlation.
Other genes can produce Dravet-like presentations. Examples include PCDH19, SCN2A, SCN8A, GABRA1, GABRG2, STXBP1, HCN1, and KCNA2, among others. Some have different inheritance patterns or treatment implications. An epilepsy panel can be preferable when the presentation is not specific or when rapid broad testing is available.
Testing Methods and Sample Types
Testing usually uses DNA from blood, saliva, or a cheek swab. Blood often provides the most consistent DNA quantity, but the inherited genotype should be the same in these routine samples. Another tissue may be needed if low-level mosaicism is suspected and blood testing is negative or ambiguous.
SCN1A sequencing
Sequencing examines the coding regions and nearby splice boundaries for single-nucleotide variants and small insertions or deletions. It detects many Dravet-associated variants but may miss whole-exon deletions, duplications, deep intronic changes, complex rearrangements, and low-level mosaicism unless the assay is designed for them.
Deletion and duplication analysis
Copy-number analysis looks for one or more missing or duplicated exons or the whole gene. Methods may include multiplex ligation-dependent probe amplification, array-based testing, quantitative polymerase chain reaction, or validated copy-number analysis from next-generation sequencing data. A negative sequence result should not be considered complete if deletion/duplication testing was not performed.
Epilepsy gene panel
A panel analyzes SCN1A with dozens or hundreds of other epilepsy genes. It can detect a non-SCN1A cause when the phenotype overlaps Dravet syndrome. Panel quality varies: laboratories differ in gene list, coverage, copy-number detection, mosaic sensitivity, and how often the panel is updated.
Exome or genome sequencing
Exome sequencing analyzes most protein-coding genes and can be useful when seizures occur with congenital anomalies, unusual neurologic features, or a broad differential diagnosis. Genome sequencing can capture coding and noncoding variants and may improve detection of structural changes. Neither method automatically guarantees complete SCN1A coverage, validated copy-number analysis, or detection of all mosaic variants, so the report’s methods remain important.
Trio testing with the child and both biological parents can clarify whether a variant is de novo and can reduce uncertainty. Parental testing should use a method sensitive enough to detect low-level mosaicism when recurrence counseling depends on the result.
Turnaround time ranges from days for rapid hospital sequencing to several weeks or months for routine testing. A clinician should not delay appropriate seizure rescue planning or avoidable medication changes while waiting for results when the clinical picture strongly suggests Dravet syndrome.
| Laboratory approach | Main strength | Important question to ask |
|---|---|---|
| SCN1A sequencing | Focused analysis of common small variant types | Are deletions, duplications, and mosaic variants included? |
| Epilepsy panel | Evaluates Dravet mimics and overlapping epilepsies | Does the panel include validated copy-number analysis? |
| Trio exome | Broad coding-gene assessment with inheritance information | Was SCN1A fully covered, and are structural variants reported? |
| Genome sequencing | Broad small and structural variant detection | Which repeats, mosaic levels, and noncoding variants are validated? |
Interpreting Positive, Uncertain, and Negative Results
A result should identify the exact SCN1A variant, classification, transcript, inheritance if known, and laboratory evidence. The words “mutation detected” are not enough to determine meaning.
Pathogenic or likely pathogenic variant
A pathogenic or likely pathogenic loss-of-function SCN1A variant strongly supports an SCN1A-related epilepsy. When the child has the typical age at onset, seizure pattern, and developmental course, it can confirm the molecular basis of Dravet syndrome. “Likely pathogenic” indicates strong evidence of disease causation and is generally used clinically like a pathogenic result, while acknowledging a small degree of uncertainty.
A positive result found before the full phenotype develops can provide an early warning rather than a certain forecast. Some infants with SCN1A pathogenic variants ultimately have milder epilepsy. Age at first seizure, seizure type, variant location and function, family history, and early course can refine risk, but prediction remains imperfect.
Variant of uncertain significance
A variant of uncertain significance, or VUS, has insufficient evidence to classify as disease-causing or benign. It should not be treated as proof of Dravet syndrome. Helpful next steps may include parental testing, detailed phenotype review, checking whether the variant has been reported in affected people, and functional studies when available.
A de novo VUS can become more suspicious, but de novo status alone does not make it pathogenic. An inherited VUS is not automatically benign because a parent may have mild epilepsy, migraine, febrile seizures, reduced penetrance, or mosaicism. The laboratory should periodically reassess the variant as new evidence appears.
Benign or likely benign variant
A benign or likely benign variant does not explain the epilepsy. Many harmless SCN1A differences occur in the general population. Such findings should not trigger Dravet-specific medication restrictions unless the clinical diagnosis independently supports them.
Negative result
A negative result means the laboratory did not find a reportable causative variant using that method. It does not exclude Dravet syndrome. The test may have missed an exon-level deletion, deep intronic variant, complex rearrangement, low-level mosaic variant, or a change in another gene. The diagnosis may also be clinical without an identifiable molecular cause.
After a negative focused test, review whether copy-number analysis was included. Broader panel, exome, or genome testing may be appropriate. Reanalysis can help when the test is several years old, the gene list was limited, or new clinical features have emerged.
Unexpected positive finding
A pathogenic SCN1A variant may be found in someone whose history does not resemble Dravet syndrome. The clinician should verify the variant classification, mechanism, and phenotype before applying Dravet treatment rules. Some SCN1A gain-of-function conditions and familial mild epilepsies require a different interpretation.
How Results Can Change Treatment and Safety
Early recognition can prevent prolonged exposure to medications that commonly aggravate seizures in classic SCN1A loss-of-function Dravet syndrome. Long-term use of sodium-channel blockers such as carbamazepine, oxcarbazepine, lamotrigine, and phenytoin can worsen seizure burden in many affected people. Lacosamide and related agents may also be problematic. These drugs are not identical, and there can be exceptional circumstances; changes should be directed by an epilepsy specialist.
Phenytoin presents a nuance. Although chronic sodium-channel blockade can aggravate Dravet syndrome, intravenous phenytoin or fosphenytoin may still be used in selected episodes of status epilepticus under specialist supervision when standard rescue measures fail. The emergency plan should state the treating team’s preferred sequence rather than relying on a blanket family interpretation.
Common maintenance options include valproate and clobazam. Stiripentol, cannabidiol, and fenfluramine have syndrome-specific evidence and regulatory approvals in various regions and age groups. Topiramate is also used. Drug selection depends on seizure types, age, interactions, organ function, adverse effects, and access. Most people require combination therapy.
SCN1A results do not identify one guaranteed effective medication. They help avoid mechanistically concerning choices and support syndrome-specific treatment, but response still varies. Blood counts, liver tests, drug levels, appetite, weight, sleep, cardiac monitoring for selected therapy, and medication interactions may require follow-up.
Every family should have a written seizure action plan. It should define when to give rescue medication, when to repeat it, when to call emergency services, and which emergency treatments have worked or failed. Prolonged convulsive seizures require rapid treatment because status epilepticus is common.
Fever management should be discussed before routine vaccinations and common illnesses. Vaccines do not cause the inherited condition, and routine immunization is generally recommended because infections and fever can provoke severe seizures. Families may use antipyretics and rescue plans around vaccination according to their clinician’s advice. Preventing infection can reduce seizure triggers.
Dravet syndrome carries a risk of sudden unexpected death in epilepsy, drowning, injury, and death during prolonged seizures. Risk counseling should be direct but sensitive. Strategies include optimizing seizure control, supervising bathing and swimming, considering nighttime monitoring, promoting medication adherence, and teaching caregivers seizure first aid. No device eliminates risk.
Genetic diagnosis can also open access to clinical trials targeting SCN1A expression or function. Experimental therapies should not be presented as proven care until controlled trials establish safety and benefit. Eligibility may depend on variant mechanism, age, prior treatment, and confirmed diagnosis.
Inheritance, Parental Mosaicism, and Family Risk
Most Dravet-associated SCN1A pathogenic variants are de novo, meaning they are not detected in routine blood samples from either parent. The child’s condition was not caused by anything the parents did before or during pregnancy.
A de novo result does not make recurrence risk zero. One parent may have germline mosaicism, in which a proportion of egg or sperm cells carries the variant even though blood testing is negative. A parent may also have low-level somatic mosaicism that a standard assay misses. Sensitive testing can sometimes detect this, but no blood test can exclude germline mosaicism completely.
If a parent carries the pathogenic variant in blood, each pregnancy may have up to a 50% chance of inheriting it under autosomal dominant inheritance. The parent’s symptoms may be much milder than the child’s. A history of febrile seizures, epilepsy, migraine, learning differences, or no apparent symptoms does not reliably predict the child’s severity.
Once the familial variant is known, reproductive options can include targeted prenatal diagnosis through chorionic villus sampling or amniocentesis, preimplantation genetic testing with in vitro fertilization, use of donor gametes, adoption, or natural conception without testing. These are personal decisions that should be discussed without pressure.
Siblings without symptoms generally do not need broad repeat testing if the variant was confirmed de novo and they are beyond the usual age of onset, but family-specific circumstances differ. Symptomatic relatives should receive clinical evaluation rather than being reassured or labeled through an informal interpretation of the child’s report.
Limits of Genotype Prediction
The variant can support diagnosis but rarely predicts the full future course. Children with similar SCN1A loss-of-function variants can differ in seizure frequency, development, gait, language, sleep, and behavior. Modifier genes, mosaicism, environmental triggers, treatment timing, seizure burden, and other unknown factors contribute.
Truncating variants are often associated with loss of function, but even this category spans a broad phenotype. Missense variants in functionally important channel regions may carry higher risk for severe disease, yet location-based rules are not absolute. Computer predictions cannot replace clinical and functional evidence.
Prediction models that combine variant information with age at seizure onset can estimate the probability of Dravet syndrome versus milder SCN1A epilepsy. These tools may help specialists counsel families after an early genetic result, but they produce probabilities, not certainty. They should not be used alone to make irreversible decisions.
A child’s current developmental trajectory and seizure pattern remain essential. If the course differs substantially from classic Dravet syndrome, the team should reconsider the diagnosis, variant mechanism, and possibility of a second condition. Dual diagnoses occur, especially when broad sequencing is performed.
Variant classifications can change. A VUS may become likely pathogenic after additional cases or functional evidence, while a previously concerning variant may be downgraded. Keep the original report and confirm how the laboratory communicates reclassification. Reanalysis is particularly important when an older test used a limited panel or outdated SCN1A interpretation.
Next Steps After Testing
After a pathogenic or likely pathogenic result, arrange review with a pediatric neurologist or epileptologist familiar with developmental epileptic encephalopathies. The visit should reconcile the genetic result with the clinical history and produce a medication plan, rescue protocol, fever strategy, developmental assessment, and safety counseling.
Ask the laboratory or clinician to document whether the variant is expected to cause loss or gain of function, whether deletion/duplication analysis was completed, and whether parental testing is recommended. Request a copy of the full report, including methods and limitations, rather than relying on a portal summary.
Developmental care should address the individual rather than a predicted syndrome average. Speech and language therapy, augmentative communication, physical therapy, occupational therapy, behavioral support, sleep evaluation, nutrition care, and school accommodations may all help. Orthopedic, rehabilitation, and mobility review becomes important when crouched gait, scoliosis, low bone density, or reduced endurance emerges.
Track seizures consistently. Record duration, triggers, side of onset, rescue medication timing, recovery, and possible adverse effects. Video can help classify events when safe to obtain. A seizure diary gives more useful information than a general impression that seizures are “better” or “worse.”
Seek emergency care according to the seizure action plan, especially for a convulsive seizure lasting 5 minutes or longer, repeated seizures without recovery, breathing difficulty, serious injury, or an event that differs from the person’s usual pattern. New developmental regression, persistent weakness, severe medication rash, marked sleepiness, or signs of serotonin or cardiac toxicity from interacting treatments also require prompt assessment.
For an uncertain or negative result, do not end the evaluation automatically. Confirm test scope, update the phenotype, consider broader testing, and set a date for reanalysis. Clinical management should continue to follow the seizure syndrome even while the molecular cause remains unresolved.
References
- International consensus on diagnosis and management of Dravet syndrome 2022 (Consensus Statement).
- Dravet syndrome: novel insights into SCN1A-mediated epileptic neurodevelopmental disorders and emerging therapeutic strategies 2025 (Review).
- Communicating a diagnosis of Dravet syndrome to parents: an international consensus 2025 (Consensus Statement).
- Use of Stiripentol in Dravet Syndrome: A Guide for Clinicians 2024 (Review).
- SCN1A Mutation—Beyond Dravet Syndrome: A Systematic Review and Narrative Synthesis 2021 (Systematic Review).
Disclaimer
This article is general education and does not diagnose Dravet syndrome or provide an individualized seizure-treatment plan. Do not stop or change antiseizure medication without the treating neurologist, because abrupt changes can provoke status epilepticus. Follow the prescribed emergency plan and seek urgent care for a prolonged seizure, breathing difficulty, serious injury, or failure to recover normally.
